Trifluridine/tipiracil hydrochloride mixture

Trifluridine/tipiracil hydrochloride mixture

• CAS Number: 733030-01-8
• UNSPSC Description: Trifluridine/tipiracil hydrochloride mixture (TAS-102) is a potent and orally active nucleoside antitumor agent. The composition of Trifluridine/tipiracil hydrochloride mixture (TAS-102) is a 1:0.5 mixture (on a molar basis) of alpha,alpha,alpha-tri-fluorothymidine (FTD) and thymidine phosphorylase inhibitor (TPI). Trifluridine/tipiracil hydrochloride mixture (TAS-102) shows the antitumor activity mainly via the inhibition of thymidylate synthase (TS) and incorporation into DNA[1][2].
• Target Antigen: Nucleoside Antimetabolite/Analog; Thymidylate Synthase
• Type: Reference compound
• Related Pathways: Apoptosis;Cell Cycle/DNA Damage
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/TAS-102.html
• Solubility: DMF : 20 mg/mL (ultrasonic)|DMSO : 2.34 mg/mL (ultrasonic;warming)|H2O : 100 mg/mL (ultrasonic)
• Smiles: O=C1N([C@H]2C[C@H](O)[C@@H](CO)O2)C=C(C(F)(F)F)C(N1)=O.O=C3N([C@H]4C[C@H](O)[C@@H](CO)O4)C=C(C(F)(F)F)C(N3)=O.O=C5NC(CN6CCCC6=N)=C(Cl)C(N5)=O.Cl
• Molecular Weight: 435.76
• References & Citations: [1]Emura T, et al. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med. 2004;13(4):545-549.|[2]Nukatsuka M, et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts. Anticancer Res. 2015;35(3):1437-1445.|[3]Limagne E, Thibaudin M, Nuttin L, et al. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. Cancer Immunol Res. 2019;7(12):1958-1969. |[4]Suzuki N, Nakagawa F, Takechi T. Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer [published correction appears in Oncol Lett. 2021 Jul;22(1):511]. Oncol Lett. 2017;14(1):639-646.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched